Jerums 2004

Methods	Country: Australia Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 66 months(median) Loss to follow‐up: 32
Participants	Inclusion criteria Age: 15‐65 years DM: Type 2 for at least 1 year Microalbuminuria: 2 of 3 consecutive measurements of UAE between 20‐200 µg/min performed on overnight urine collections BP: Supine 140/90 mm Hg Perindopril group Number: 23 Age: 50 (2) Sex (M/F): 14/9 Placebo group Number: 27 Age: 53 (1) Sex (M/F): 15/12 Exclusion criteria Non‐diabetic renal disease SCr > 200 µmol Haematuria Cardiac failure Hypertension Concurrent systemic disease Poor diabetic control (HbA1c > 10%) Serum potassium > 5mmol/L Recurrent UTI Patients at high risk for pregnancy Patients with another condition or therapy that might pose a risk to the patient or confound the results of the study
Interventions	Perindopril group 2‐8 mg/d Placebo group Co‐interventions Diuretics, CCB, beta‐blockers if blood pressure remained uncontrolled.
Outcomes	AER Development of macroproteinuria or reversal to the normoalbuminuric range
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear